MedTrace Logo

Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration

NCT07221656 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2026-04-02

No results posted yet for this study

Summary

This study evaluates the median duration of therapeutic serum asparaginase activity (SAA) levels after administration of calaspargase pegol (Cal-PEG) and the potential association between peak SAA levels and duration of therapeutic levels with toxicity in pediatric patients with acute lymphoblastic leukemia or lymphoma.

Conditions

  • Childhood Acute Lymphoblastic Leukemia
  • Childhood Lymphoblastic Lymphoma

Interventions

OTHER

Non-Interventional Study

Non-interventional study

Sponsors & Collaborators

Principal Investigators

  • Madeleine B. O'Keefe, MD · Mayo Clinic in Rochester

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2027-02-01
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07221656 on ClinicalTrials.gov